2-(1-trityl-1H-imidazol-4-yl)acetaldehyde

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: 2-(1-trityl-1H-imidazol-4-yl)acetaldehyde
• 英文别名: 2-(1-Tritylimidazol-4-yl)acetaldehyde
• 化学式: C₂₄H₂₀N₂O
• 分子量: 352.436
• InChiKey: WLYVAVCZXRPTIH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  34.9
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  甲基(1-trityl-1H-imidazol-4-yl)乙酸酯 在 二异丁基氢化铝 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 4.5h， 生成 2-(1-trityl-1H-imidazol-4-yl)acetaldehyde
  参考文献：
  名称：

  α-氨基酸等位α-氨基四唑

  摘要：

  已经完成了所有20种常见的天然蛋白原性和其他4种α-氨基酸-等位α-氨基四唑的合成，其中羧基被等位5-四唑基取代。简短的过程涉及使用关键的Ugi四唑反应，然后进行脱保护化学反应。四唑基团对羧酸具有生物立体异构性，并广泛用于药物化学和药物设计中。令人惊讶的是，到目前为止，尚不知道几种常见的α-氨基酸-等位α-氨基四唑。因此，快速合成获得该化合物类和非天然衍生物对于推动该领域具有重大意义。

  DOI：

  10.1002/chem.201504520

文献信息

• Method of treating cancer
  申请人：——

  公开号：US20030220241A1

  公开（公告）日：2003-11-27

  The present invention relates to methods of treating cancer using a combination of a compound which is a PSA conjugate and a compound which is a inhibitor of prenyl-protein transferase, which methods comprise administering to said mammal, either sequentially in any order or simultaneously, amounts of at least two therapeutic agents selected from a group consisting of a compound which is a PSA conjugate and a compound which is a inhibitor of prenyl-protein transferase. The invention also relates to methods of preparing such compositions.

  本发明涉及使用一种PSA共轭物和一种前脂蛋白转移酶抑制剂的组合治疗癌症的方法，该方法包括向所述哺乳动物施用来自以下组中选择的至少两种治疗剂的量，所述组包括一种PSA共轭物和一种前脂蛋白转移酶抑制剂，所述治疗剂可以顺序给药或同时给药。该发明还涉及制备这种组合物的方法。
• Imidazole-containing inhibitors of farnesyl protein transferase
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：EP0675112A1

  公开（公告）日：1995-10-04

  Inhibition of farnesyl transferase, which is an enzyme involved in ras oncogene expression, is effected by compounds of the formula their enantiomers, diastereomers, and pharmaceutically acceptable salts, prodrugs, and solvates, wherein:    G is    G¹ is    G² is or -NR¹⁰-CH(Q¹)-;    J, K and L are each, independently, N, NR⁹, O, S or CR¹⁰ with the provisos that only one of the groups J, K and L can be O or S, and at least one of the groups J or L must be N, NR⁹, O or S to form a fused five-membered heteroring; the bond between J and K or K and L may also form one side of a phenyl ring fused to the fused five-membered heteroring;    Q is aryl;    Q¹, A¹ and A² are each, independently, H, alkyl, substituted alkyl, phenyl or substituted phenyl;    G³ is R¹¹, -C(O)OR¹¹, -C(O)NR¹¹R¹², 5-tetrazolyl, -C(O)N(R¹³)OR¹¹, -C(O)NHSO₂R¹⁴ or -CH₂OR¹¹;    G⁴ is attached at the 1, 2, 4 or 5 position and optionally substituted, at any of the available position or positions on the ring, with halo, alkyl or substituted alkyl having 1 to 20 carbon atoms, alkoxy, aryl, aralkyl, hydroxy, alkanoyl, alkanoyloxy, amino, alkylamino, dialkylamino, alkanoylamino, thiol, alkylthio, alkylthiono, alkylsulfonyl, sulfonamido, nitro, cyano, carboxy, carbamyl, N-hydroxycarbamyl, N-alkylcarbamyl, N-dialkylcarbamyl, alkoxycarbonyl, phenyl, substituted phenyl, or a combinaton of these groups;    Y and Z are each, independently, -CH₂- or -C(O)-;    R¹ - R¹⁴ are each, independently, H or alkyl having 1 to 20 carbon atoms;    R⁷, R⁸ and R¹⁴ may also be aryl or aralkyl, and R³, R⁹, R¹¹, R¹² and R¹³ may also be aralkyl;    m, n and p are each, independently, 0 or an integer from 1 to 2;    q is 0 or an integer from 1 to 4; and    the dotted line represents an optional double bond.

  抑制法尼醇转移酶是一种参与ras癌基因表达的酶，其受化合物的影响，其化合物包括其对映异构体、非对映异构体和药用可接受的盐、前药和溶剂化合物，其中： G为G¹为G²为或-NR¹⁰-CH(Q¹)-；J、K和L分别独立地为N、NR⁹、O、S或CR¹⁰，但有以下规定：J、K和L中只有一个可以是O或S，且J或L中至少有一个必须是N、NR⁹、O或S以形成融合的五元杂环；J和K之间的键或K和L之间的键也可以形成与融合的五元杂环融合的苯环的一侧；Q为芳基；Q¹、A¹和A²分别独立地为H、烷基、取代烷基、苯基或取代苯基；G³为R¹¹、-C(O)OR¹¹、-C(O)NR¹¹R¹²、5-四唑基、-C(O)N(R¹³)OR¹¹、-C(O)NHSO₂R¹⁴或-CH₂OR¹¹；G⁴附着在1、2、4或5位，并可选择地取代在环上的任何可用位置或位置，取代基为卤素、烷基或取代烷基（碳原子数为1至20）、烷氧基、芳基、芳基烷基、羟基、烷酰基、烷酰氧基、氨基、烷基氨基、二烷基氨基、烷酰氨基、硫醇基、烷基硫基、烷基硫酰基、磺酰胺基、硝基、氰基、羧基、氨基甲酰基、N-羟基氨基甲酰基、N-烷基氨基甲酰基、N-二烷基氨基甲酰基、烷氧基羰基、苯基、取代苯基或上述基团的组合；Y和Z分别独立为-CH₂-或-C(O)-；R¹-R¹⁴分别独立为H或烷基（碳原子数为1至20）；R⁷、R⁸和R¹⁴也可以是芳基或芳基烷基，R³、R⁹、R¹¹、R¹²和R¹³也可以是芳基烷基；m、n和p分别独立地为0或1至2的整数；q为0或1至4的整数；虚线表示可选的双键。
• [EN] ACYCLIC CXCR4 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS ACYCLIQUES DE CXCR4 ET LEURS UTILISATIONS
  申请人：X4 PHARMACEUTICALS INC

  公开号：WO2019126106A1

  公开（公告）日：2019-06-27

  The present invention relates to compounds and methods useful for modulation, e.g. inhibition, of C-X-C receptor type 4 (CXCR4). The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using the compositions in the treatment of various disorders.

  本发明涉及化合物和方法，用于调节，例如抑制，C-X-C受体类型4（CXCR4）。该发明还提供了包含本发明化合物的药学上可接受的组合物，并提供了使用这些组合物治疗各种疾病的方法。
• Inhibitors of prenyl-protein transferase
  申请人：——

  公开号：US20020010184A1

  公开（公告）日：2002-01-24

  The present invention comprises piperazinone-containing compounds which inhibit prenyl-protein transferases, including famesyl-protein transferase and geranylgeranyl-protein transferase type I. Such therapeutic compounds are useful in the treatment of cancer.

  该发明涉及含有哌嗪酮类化合物，可抑制前列蛋白转移酶，包括法美基蛋白转移酶和戈楞基蛋白转移酶I型。这种治疗性化合物对癌症的治疗具有用处。
• Geranylgeranyl transferase inhibitor screening assay
  申请人：——

  公开号：US20020072081A1

  公开（公告）日：2002-06-13

  The present invention is directed toward a GGTase-I competitive binding assay which can be used to determine the relative GGTase-I inhibitory potency of test compounds. The present invention is also directed toward radiolabeled geranylgeranyl-protein transferase type-I inhibitor compounds which are useful to label GGTase-I in assays, whether cell-based, tissue-based or in whole animal.

  本发明涉及一种GGTase-I竞争结合测定法，可用于确定测试化合物的相对GGTase-I抑制效力。本发明还涉及放射标记的戊二醇基蛋白转移酶-I抑制剂化合物，可用于在细胞、组织或整个动物中标记GGTase-I。